deflazacort + rifampin

Deflazacort + rifampin is a combination of two pharmaceutical agents. Deflazacort is a synthetic corticosteroid prodrug that is rapidly converted in the body to its active metabolite, 21-desDFZ. This metabolite acts as an agonist at the glucocorticoid receptor and exerts anti-inflammatory and immunosuppressive effects. Deflazacort is primarily indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 5 years and older[2][5][8]. Rifampin is an antibiotic belonging to the rifamycin class; it inhibits bacterial DNA-dependent RNA polymerase and is used mainly for treating tuberculosis and as prophylaxis against *Neisseria meningitidis*[1]. When administered together, there are significant pharmacokinetic interactions—rifampin strongly induces CYP3A4 enzymes, which markedly reduces exposure to deflazacort’s active metabolite (by up to 90%), potentially leading to loss of efficacy[2][4][6].

Brand names

EmflazaRifadinRimactane